risedronic acid has been researched along with Cerebral Palsy in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bean, J; Cassedy, A; Cohran, V; Hawkins, A; Heubi, J | 1 |
| Hosoda, N; Ishii, M; Iwasaki, T; Nakamura, S; Takei, K; Yokota, Y | 1 |
| Ishii, M; Iwasaki, T; Nonoda, Y | 1 |
3 trial(s) available for risedronic acid and Cerebral Palsy
| Article | Year |
|---|---|
Oral risedronate sodium improves bone mineral density in non-ambulatory patients: a randomized, double-blind, placebo controlled trial.
Topics: Absorptiometry, Photon; Adolescent; Adult; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Cerebral Palsy; Child; Collagen Type I; Double-Blind Method; Etidronic Acid; Female; Humans; Lumbar Vertebrae; Male; Osteocalcin; Peptides; Risedronic Acid; Treatment Outcome; Young Adult | 2013 |
Secondary osteoporosis in long-term bedridden patients with cerebral palsy.
Topics: Absorptiometry, Photon; Adolescent; Alkaline Phosphatase; Anticonvulsants; Benzodiazepines; Biomarkers; Bone Density; Bone Density Conservation Agents; Cerebral Palsy; Child; Child, Preschool; Clobazam; Collagen Type I; Double-Blind Method; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Humans; Hydroxycholecalciferols; Infant; Isoxazoles; Lumbar Vertebrae; Male; Osteoporosis; Peptides; Retrospective Studies; Risedronic Acid; Severity of Illness Index; Time Factors; Treatment Outcome; Zonisamide | 2008 |
Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Cerebral Palsy; Child; Child, Preschool; Collagen Type I; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Humans; Hydroxycholecalciferols; Infant; Male; Osteoporosis; Peptides; Risedronic Acid; Treatment Outcome | 2012 |